AC
KDNY

Ascend Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ascend Capital’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,252
Closed -$1.08M – 260
2017
Q3 		$1.08M Buy
+20,252
New +$1.2M 0.04% 149

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ascend Capital's KDNY Position: Q4 2017 in Review

Ascend Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2017, closing a stake of 20,252 shares — an estimated $1.08M sold.

Ascend Capital first reported a position in KDNY in Q3 2017 and held it in 1 quarter. The position peaked at $1.08M in Q3 2017. 94 funds tracked by Wall St. Rank hold KDNY as of Q4 2017.

  • Ascend Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Ascend Capital sold 20,252 Chinook Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $1.08M.
  • Ascend Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Ascend Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $1.08M in Q3 2017.
  • 94 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.